A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy

BACKGROUND: A5350, a phase II, randomized, double-blind study, evaluated the safety and tolerability of the probiotic Visbiome Extra Strength (ES) over 24 weeks and measured effects on inflammation and intestinal barrier function. METHODS: The primary outcome was change in soluble CD14 (sCD14) level...

Descripción completa

Detalles Bibliográficos
Autores principales: Presti, Rachel M, Yeh, Eunice, Williams, Brett, Landay, Alan, Jacobson, Jeffrey M, Wilson, Cara, Fichtenbaum, Carl J, Utay, Netanya S, Dube, Michael P, Klingman, Karin L, Estes, Jacob D, Flynn, Jacob K, Loftin, Amanda, Brenchley, Jason M, Andrade, Adriana, Kitch, Douglas W, Overton, Edgar T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651169/
https://www.ncbi.nlm.nih.gov/pubmed/34888397
http://dx.doi.org/10.1093/ofid/ofab550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651169/
https://www.ncbi.nlm.nih.gov/pubmed/34888397
http://dx.doi.org/10.1093/ofid/ofab550

Ejemplares similares